title: Establishment and characterization of a novel VEGF-producing HHV-8-unrelated PEL-like lymphoma cell line, OGU1.
abstract: Primary effusion lymphoma (PEL) is a rare B-cell lymphoma subtype that is characterized by lymphomatous effusion without the presence of masses, and it typically occurs in human immunodeficiency virus (HIV)-infected individuals. Lymphoma cells are universally positive for human herpesvirus 8 (HHV-8). Recently, a cavity-based effusion lymphoma that is similar to PEL without HHV-8 infection, called HHV-8-unrelated PEL-like lymphoma, has been reported in non-HIV-infected individuals. However, the pathophysiology of this lymphoma is largely undefined. We established a novel B-cell line OGU1 derived from a patient with HHV-8-unrelated PEL-like lymphoma. Notably, OGU1 cells produced vascular endothelial growth factor (VEGF) and expressed VEGF receptor 1, whose inhibitors retarded cell growth. Because VEGF acts as a vascular permeability and growth factor, it could play a role, at least in part, in the pathogenesis of this unique lymphoma. Thus, the OGU1 cell line is useful for the investigation of HHV-8-unrelated PEL-like lymphoma.
authors.affiliation: Medical Center East, Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan.|Nishiogu Clinic, Tokyo, Japan.
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Kawauchi
authors.affiliation: Medical Center East, Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Toshie
authors.initials: T
authors.lastname: Ogasawara
authors.affiliation: Medical Center East, Department of Surgical Pathology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Motohiko
authors.initials: M
authors.lastname: Aiba
authors.affiliation: Medical Center East, Department of Surgical Pathology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Mariko
authors.initials: M
authors.lastname: Fujibayashi
authors.affiliation: Center of CKD and Lifestyle Related Diseases, Edogawa Hospital, Ichikawa city, Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sanaka
authors.affiliation: Medical Center East, Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sakura
authors.affiliation: Institute of Physiology and Medicine, Jobu University, Takasaki, Japan.|Institute of Medical Science, University of Tokyo, Tokyo, Japan.
authors.forename: Masabumi
authors.initials: M
authors.lastname: Shibuya
mesh_terms: D000368:Aged; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology*; D002199:Capillary Permeability; D045744:Cell Line, Tumor; D018703:Founder Effect; D015870:Gene Expression; D006566:Herpesviridae Infections / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D019288:Herpesvirus 8, Human / Q000472:pathogenicity / Q000502:physiology; D006801:Humans; D054685:Lymphoma, Primary Effusion / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics / Q000378:metabolism
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1
keywords: B-cell lymphoma; PEL-like lymphoma; Primary effusion lymphoma; vascular endothelial growth factor